Ropes & Gray represented Alexion Pharmaceuticals, Inc., a global biopharmaceutical company focused on serving patients and families affected by rare diseases, in its acquisition of all outstanding shares in Wilson Therapeutics by way of a tender offer, through a wholly-owned subsidiary. The total equity value of the transaction amounts to approximately $855 million. The transaction was announced on April 11, 2018 and is expected to close in the second quarter of 2018, subject to customary closing conditions.
Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare copper-mediated disorders. Wilson Therapeutics’ product, WTX101, is in Phase 3 development as a treatment for Wilson disease.
Ropes & Gray acted as U.S. legal advisor. The team is being led by securities & public companies partner Zachary Blume and antitrust counsel Deidre Johnson.
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.